EP3030142A1 - Intra-abdominal pressure to promote hemostasis and survival - Google Patents
Intra-abdominal pressure to promote hemostasis and survivalInfo
- Publication number
- EP3030142A1 EP3030142A1 EP14835065.5A EP14835065A EP3030142A1 EP 3030142 A1 EP3030142 A1 EP 3030142A1 EP 14835065 A EP14835065 A EP 14835065A EP 3030142 A1 EP3030142 A1 EP 3030142A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pressure
- cavity
- foam
- steady state
- mmhg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/1219—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00637—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for sealing trocar wounds through abdominal wall
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00641—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closing fistulae, e.g. anorectal fistulae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00646—Type of implements
- A61B2017/00654—Type of implements entirely comprised between the two sides of the opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00898—Material properties expandable upon contact with fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B2017/12004—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord for haemostasis, for prevention of bleeding
Definitions
- In situ forming polymer foams such as the Arsenal Foam Technology commercialized by Arsenal Medical (Watertown, MA), have a number of important biomedical applications including the prevention or treatment of hemorrhage, particularly from noncompressible or difficult-to-visualize wounds, vascular embolization, arteriovenous malformation, AV fistulas, abdominal aortic aneurysm, space filling and bulking (e.g. following surgical resection, or for cosmetic purposes), prevention of tissue adhesion, hernia repair, prevention or treatment of reflux, and temporary or permanent occlusion of body lumens for a variety of applications including sterilization, prevention of calculus migration during lithotripsy, and other applications.
- hemorrhage particularly from noncompressible or difficult-to-visualize wounds
- vascular embolization arteriovenous malformation
- AV fistulas arteriovenous malformation
- abdominal aortic aneurysm abdominal aortic aneurysm
- the diversity of applications for in situ forming foams reflects significant advantages possessed by such foams relative to existing technology, including, without limitation their incorporation of well characterized, biocompatible materials; the ability to deliver in situ forming foams to closed cavities, for example intravascularly; the ability to deliver in situ forming foams to difficult-to-access body sites; the ability of in situ forming foams to expand into empty space, potential space, or into space filled with blood, support surrounding tissues, and the ability of the foam to fill a body cavity.
- Foams are typically generated in situ by delivering and mixing multiple liquid-phase components (such as a polyol component and an isocyanate component, which form a polyurethane foam). Pores within the foam may be formed by a blowing reaction and/or by the entrainment of gas before or during foam formation, and the foam may harden through the formation of cross-links between prepolymers and/or cross-linking agents. When deployed into a body cavity, the liquid components react, driving the expansion and hardening of the foam. The foam applies pressure to the boundaries of the cavity in a dose dependent and time-dependent manner, for example as shown in the pressure curves of Fig. 1.
- the shapes of these curves are determined by, among other things, the composition and quantity of liquid phase components applied to the body cavity, which govern the rates of the blowing and cross-linking reactions and foam properties (e.g., density or volume expansion, stiffness, pore size, hydrophilicity, absorption capacity).
- in situ forming foams are particularly well suited to treating noncompressible hemorrhages in challenging settings, including the battlefield and rural or wildnerness settings far from hospital trauma centers.
- in situ forming foams have not been widely used because of the technical challenges associated with developing suitable in situ foaming formulations for different applications and delivering of these formulations to body cavities in quantities sufficient to arrest hemorrhages without causing undesirable side effects of excessive pressure such as compartment syndrome.
- in situ forming foams should extend patient survival times for a period sufficient to permit evacuation of patients to stations or centers where hemorrhages can be surgically treated.
- Embodiments of the current invention address the challenges described above by providing, in one aspect, a method for treating hemorrhage within a body cavity or potential space that includes applying pressure to an interior boundary of the cavity, including pressure to the injury itself, which pressure is characterized by a transient peak value and by at least one steady state value.
- the transient peak value is between 22 mmHg and about 86 mmHg (e.g. 20, 51 and 84 mmHg).
- the steady state value is, in various embodiments, between about 14 mmHg and about 28 mmHg (e.g. 14 or 28 mmHg).
- Pressure may be applied, in certain embodiments, by an article placed into the closed cavity, and the article can be a foam which is formed inside of the cavity by applying a formulation that includes one or more liquid phases into the cavity.
- the steady state pressure occurs within three minutes and is followed by the steady state value.
- the steady state value may be, in some cases, 30%, 50% or 90% of the transient peak value.
- the invention in another aspect, relates to a kit for treating hemorrhage in closed cavities that includes (i) a formulation for forming a foam when disposed into a body, which formulation includes at least one liquid phase, and (ii) instructions for performing the method set forth above.
- Fig. 1 plots intra-abdominal pressure over time for four doses of an in situ forming foam in a severe porcine liver hemorrhage model compared with an untreated control.
- Fig. 2 plots survival curves for porcine treated with four doses of an in situ forming foam in a severe liver hemorrhage model compared with an untreated control.
- Fig. 3 plots the survival times of 81 animals treated either with in situ forming foams or no foam treatment controls against the peak intra-abdominal pressure measured in each animal in a severe liver hemorrhage model.
- Fig. 4 plots the survival times of 81 animals treated either with in situ forming foams or no foam treatment control animals against the intra-abdominal pressure measured at 30-minutes post injury in each animal in a severe l iver hemorrhage model.
- Fig. 5 plots intra-abdominal pressure over time for two doses of an in situ forming foam in a severe arterial hemorrhage model.
- Fig. 6 plots survival curves for animals treated with two doses of an in situ forming foam in a severe arterial hemorrhage model.
- Fig. 7 plots intra-abdominal pressure over time for animals given in situ forming foam, gas insufflation, or no treatment.
- Fig. 8 plots intra-abdominal pressure over time in recently deceased cadaver samples following delivery of an in situ forming foam formulation.
- the second model was a lethal arterial injury, in which a wire was placed around the external iliac artery and externalized percutaneously as above as described in Duggan MJ, et al. "Development of a lethal, closed-abdomen, arterial hemorrhage model in non-coagulopathic swine.” J. Surg. Res. 2014; 187: 536-541 ("Duggan 2"), which is hereby incorporated by reference in its entirety and for all purposes. Also as above, following closure of a midline incision, the wire was pulled, resulting again in a severe, uncontrolled, closed cavity injury, and massive hypotension which was over 80% lethal at one hour in the absence of intervention.
- IAP intraabdominal pressure
- a patient suffering from a closed-cavity or non-compressible hemorrhage is treated by administering an in situ forming foam as described in Switzerlandates I and II and Sharma I and II.
- the liquid phases include (a) an isocyanate to generate gas and crosslink and (b) a polyol to control the foam properties upon reaction with the isocyanate.
- the formulation reacts to generate a foam within two minutes of its deployment into the body, and is characterized by the parameters shown in Table 1, below.
- administration of foams of the invention cause a rapid, transient increase or spike in pressure within the cavity or within a portion of a boundary of a cavity containing a hemorrhage. Following the spike the pressure preferably remains elevated at a steady-state value or within a steady-state range that is less than the peak pressure for an extended period of time.
- Exemplary temporal pressure profiles which include spikes and steady-state pressure ranges are shown for various doses of foam in Fig. 1.
- the steady-state pressure may persist for a suitable interval which permits evacuation of the patient to a site where medical treatment is available, for instance about 60, 90, 120, 150, 180, 210 or 240 minutes, or longer.
- the magnitude of the pressure spike may vary depending on the formulation and dose used, so that different device formulations and/or doses might be selected to suit different applications and different patient body sizes or types. Additionally, the magnitude of the steady state pressure may be dose dependent, and may be affected by interventions which affect the rate of foaming, cross-linking, or degradation of the foam. For instance, in some embodiments, a user may decrease a steady-state pressure by applying a material which tends to degrade the foam in a quantity selected to rapidly degrade a portion of the foam. In other embodiments, the delivery system may modulate peak or steady state pressure through a dose modulation feature, a relief valve, or a similar feature. Exemplary materials are described in Sharma I and in Switzerlandates I and II. Delivery systems and methods suitable for use in connection with methods of the present invention are set forth in Sharma II.
- the pressure spike ensures that sufficient force is applied to the boundaries of the body cavity and/or the injury site to effectively close hemorrhaging.
- Studies by others have generally shown that sustained, elevated pressure within body cavities, and particularly elevated IAP above 20 mmHg can have adverse effects on patients.
- Vivier et al. (“Effects of increased intra-abdominal pressure on central circulation", Br. J. Anaesthesia 96(6): 701-7 (2006), which is hereby incorporated by reference for all purposes), found vascular changes including increases in left ventricular end- diastolic area and pressure (markers of increased cardiac preload) were significantly increased at elevated IAP values.
- compartment syndrome a condition characterized by pain, paralysis, paresthesia, and other undesirable effects including, in some instances, lethality.
- compartment syndrome increased compartmental pressure limits blood supply to muscles and nerves within the compartment.
- prior art systems and methods have been designed to limit applied compartmental pressures to values below about 20 mmHg or about 30 mmHg.
- Fig. 1 pressure profiles such as those shown in Fig. 1 are effective in treating life-threatening non-compressible hemorrhage in swine (as discussed in greater detail below), while avoiding complications associated with compartment syndrome.
- a transient application of high-pressure within a cavity rapidly prevents ongoing hemorrhage from injured vasculature and permits clots formation in the absence of robust ongoing flow.
- the application of a lower, but still elevated steady-state pressure maintains hemostasis.
- the inventors have also found that, while pressure alone is sufficient to achieve some reduction in hemorrhage, and to improve survivability from non-compressible hemorrhage, the application of pressure by a foam such as an in situ forming foam or another material having a solid or partially solid surface improves the efficacy of the systems and methods of the invention. While pressures may be applied by a variety of means, including gas or liquid insufflation, the use of foams to treat hemorrhages in cavities may be particularly advantageous.
- foams for treatment of hemorrhages in cavities
- other treatment systems and methods are within the scope of the invention insofar as it is possible to achieve the pressure profiles discussed above using these systems and methods.
- gels, elastomeric solids, pre-formed foams, or combinations of foams and liquids or foams and gasses can be utilized to apply pressure to the cavity or a portion of the boundary of the cavity (including injured tissue and tissues adjacent to injured tissue).
- materials which undergo phase changes within cavities for example reverse thermosensitive materials including poloxamers, and electromechanical or hydraulic devices can be used to deliver pressure to hemorrhages within cavities.
- pressure may be delivered via materials, systems and devices deployed either within the cavity or outside of the cavity (e.g. adjacent to the cavity).
- the cavity is constricted from the outside, for example by constricting the abdomen from the exterior.
- Pressure can be generated in certain models through the delivery and/or removal of material (e.g. liquid, gas, gel, foam) to apply pressure to the cavity, and the pressure applied may be controlled manually by an end user, mechanically by a governing device such as a valve (e.g. a check valve), or by computerized means.
- material e.g. liquid, gas, gel, foam
- a governing device such as a valve (e.g. a check valve), or by computerized means.
- Example 1 Dose-dependent changes in spike and steady-state pressure values and survival in a hepatic hemorrhage model.
- In situ forming foams were delivered in the grade V hepatic-portal model described above. Animals were given 64 ml, 85 ml, 100 ml or 120 ml of liquid-phase in situ forming foam formulations, or sham treatment in the case of control animals, and IAP was measured over an interval of 3 hours. As shown in Fig. 1, control animals showed only a minor increase in IAP over the first 20 minutes of the experiment, while foam-treated animals displayed dose-dependent changes in spike pressures and steady-state pressures. In addition, survival was quantitated for animals in each treatment category.
- Foam dosages in the swine models used herein are likely to be larger than the volumes used in humans, owing to differences in the volume of the abdominal cavity.
- the Kaplan-Meier graph of all groups is shown in Fig. 2. Median survival time was 180 (180 - 180) minutes at 120mL, 180 (161-180) minutes at lOOmL, 89 (81-158) minutes at 85mL, and 55 (40-68) at 64mL.
- Peak IAP (mmHg) Mean survival time (min)
- FIG. 4 plots the IAP measured 30 minutes after injury against survival time, and indicates that survival improved at steady-state pressures at or above 18 mmHg, and improved further at steady state pressures at or above 28 mmHg (see Table 3):
- Example 2 Dose-dependent changes in spike and steady-state pressure values and survival in an arterial hemorrhage model.
- Table 4 depicts six exemplary experiments in which varying quantities of an in situ foaming formulation was administered to porcine in a liver hemorrhage and an iliac hemorrhage model.
- Example 3 Approximation of survival effects by gas insufflation with foam-like pressure kinetics.
- the foams disclosed above and used in the previous examples generated pressure spikes by one or more of a rapid increase in the volume of the foam, gas generated from the blowing reaction, gas generated and not fully contained by the foam, etc.
- the reduction in pressure to the steady state values may have been due to one or more of a viscoelastic response of the tissues in the abdominal cavity, a change in fundamental abdominal volume, possibly caused by the relaxation of tissues in the abdomen, a reduction in the volume of the foam, gas transfer, etc.
- Example 4 Observation of spike-and-steady state pressure profiles in recently deceased human subjects.
- the Arsenal Foam System was deployed in recently deceased human subjects. Subjects with no abdominal pathology or prior surgery were identified and informed consent was obtained from family members post-mortem. Within three hours of death, the abdomen was accessed and 1500mL fluid was added to simulate severe hemorrhage. Self-expanding polyurethane foam was administered at multiple doses using a prototype delivery system. Intraabdominal pressure was monitored as a function of time for 15 minutes, after which the foam was removed and contact with abdominal tissues was evaluated.
- Foam administration resulted in a rapid, transient, and dose-dependent peak in intraabominal pressure following deployment in humans. Notably, the shape of the curves was similar to that observed in animal models, suggesting that the foam system results in a characteristic intraabdominal pressure following deployment.
- a reference to "A and/or B,” when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A without B (optionally including elements other than B); in another embodiment, to B without A (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- cavity' as used herein means closed body compartments such as the abdominal cavity, the thoracic cavity, etc., as well as cavities that are open, such as junctional wounds, and "pseudocavities" in which at least one boundary of the cavity is defined by a structure other than an organ or a tissue, (e.g. a bandage).
- the term “substantially,” “approximately” or “about” means plus or minus 10% (e.g., by weight or by volume), and in some embodiments, plus or minus 5%.
- Reference throughout this specification to "one example,” “an example,” “one embodiment,” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present technology.
- the occurrences of the phrases “in one example,” “in an example,” “one embodiment,” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example.
- the particular features, structures, routines, steps, or characteristics may be combined in any suitable manner in one or more examples of the technology.
- the headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the claimed technology.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Surgical Instruments (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361864368P | 2013-08-09 | 2013-08-09 | |
PCT/US2014/050332 WO2015021375A1 (en) | 2013-08-09 | 2014-08-08 | Intra-abdominal pressure to promote hemostasis and survival |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3030142A1 true EP3030142A1 (en) | 2016-06-15 |
EP3030142A4 EP3030142A4 (en) | 2017-08-09 |
Family
ID=52461959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14835065.5A Withdrawn EP3030142A4 (en) | 2013-08-09 | 2014-08-08 | Intra-abdominal pressure to promote hemostasis and survival |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3030142A4 (en) |
JP (1) | JP2016531668A (en) |
AU (1) | AU2014305771A1 (en) |
CA (1) | CA2919856A1 (en) |
IL (1) | IL244011A0 (en) |
WO (1) | WO2015021375A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10293076B2 (en) | 2011-08-12 | 2019-05-21 | Arsenal Medical, Inc. | Intra-abdominal pressure to promote hemostasis and survival |
US9358042B2 (en) | 2013-03-13 | 2016-06-07 | The Spectranetics Corporation | Expandable member for perforation occlusion |
US10499892B2 (en) | 2015-08-11 | 2019-12-10 | The Spectranetics Corporation | Temporary occlusion balloon devices and methods for preventing blood flow through a vascular perforation |
US10449336B2 (en) | 2015-08-11 | 2019-10-22 | The Spectranetics Corporation | Temporary occlusions balloon devices and methods for preventing blood flow through a vascular perforation |
AU2020401226A1 (en) | 2019-12-13 | 2022-06-09 | Massachusetts Institute Of Technology | Tissue catalyzed growth of polymer as epithelial linings for therapy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6520977B2 (en) * | 1999-12-06 | 2003-02-18 | Hadi Piraka | Uterine balloon apparatus and method |
US20040013715A1 (en) * | 2001-09-12 | 2004-01-22 | Gary Wnek | Treatment for high pressure bleeding |
US8828358B2 (en) * | 2008-03-11 | 2014-09-09 | Materials Modifications, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide |
US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
US10420862B2 (en) * | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
EP2741788A4 (en) * | 2011-08-14 | 2015-03-25 | Materials Modification Inc | Method and composition for in situ formation of an artificial blockage to control blood loss |
US8993831B2 (en) * | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
-
2014
- 2014-08-08 CA CA2919856A patent/CA2919856A1/en not_active Abandoned
- 2014-08-08 EP EP14835065.5A patent/EP3030142A4/en not_active Withdrawn
- 2014-08-08 JP JP2016533465A patent/JP2016531668A/en active Pending
- 2014-08-08 AU AU2014305771A patent/AU2014305771A1/en not_active Abandoned
- 2014-08-08 WO PCT/US2014/050332 patent/WO2015021375A1/en active Application Filing
-
2016
- 2016-02-08 IL IL244011A patent/IL244011A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2015021375A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2016531668A (en) | 2016-10-13 |
WO2015021375A1 (en) | 2015-02-12 |
AU2014305771A1 (en) | 2016-02-18 |
CA2919856A1 (en) | 2015-02-12 |
EP3030142A4 (en) | 2017-08-09 |
IL244011A0 (en) | 2016-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9522215B2 (en) | Intra-abdominal pressure to promote hemostasis and survival | |
US10653422B2 (en) | Intra-abdominal pressure to promote hemostasis and survival | |
WO2015021375A1 (en) | Intra-abdominal pressure to promote hemostasis and survival | |
US9623143B2 (en) | Foam-based medical treatments | |
US20160082144A1 (en) | In-situ forming foams for embolizing or occluding a cavity | |
AU2016350051B2 (en) | Hemostatic mixture of cellulose-based short and long fibers | |
JP2022506896A (en) | Foam composition, foam matrix and method | |
Su et al. | Absolute ethanol embolization of infiltrating-diffuse extracranial arteriovenous malformations in the head and neck | |
JP2006521180A (en) | Medical device with hydrogel yarn | |
WO2007142757A3 (en) | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions | |
US20160120528A1 (en) | Hydrogel Pressure Sealant System | |
Dowling et al. | Determination of efficacy of a novel alginate dressing in a lethal arterial injury model in swine | |
Willinsky et al. | Spinal epidural arteriovenous fistulas: arterial and venous approaches to embolization. | |
ES2875098T3 (en) | High efficiency hemostatic adhesive polymer scaffold | |
WO2009100435A2 (en) | Sclerotherapy for varicose veins | |
Rappold et al. | Surgical adjuncts to noncompressible torso hemorrhage as tools for patient blood management | |
EP3539571A1 (en) | Systems and methods relating to medical applications of synthetic polymer formulations | |
JP2017522118A (en) | Heat-sensitive adhesion preventing composition and use thereof | |
US10293076B2 (en) | Intra-abdominal pressure to promote hemostasis and survival | |
Naar et al. | Chitosan-based lifefoam improves survival in lethal noncompressible abdominal bleeding in swine | |
US20120053566A1 (en) | Method for treatment of emphysema | |
RU2810584C1 (en) | Thermo-controlled composition to stop bleeding temporary | |
ES2864658T3 (en) | Biological adhesives and sealants and methods of using them | |
Jones et al. | 3: 54 PM Abstract No. 405 GPX by Fluidx Medical Technology: a new proprietary in situ setting embolic agent that combines the benefits of coils, gel beads, and liquid embolics | |
RU2819603C1 (en) | Composition for temporary control of bleeding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160219 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170711 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 5/00 20060101AFI20170706BHEP Ipc: A61B 5/02 20060101ALI20170706BHEP Ipc: A61B 5/022 20060101ALI20170706BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180208 |